Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split

BRAINTREE, Mass., Oct. 29, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%.  Excluding restructuring, transformation, integration and transaction costs, adjusted net income was $23.5 million, up 26%, and adjusted earnings per share were $0.90, up 25%.  Organic net revenue, exclusive of the recently acquired whole blood business, was $189.6 million, up 6%. Excluding currency impacts, net revenue was up 22% in total and 6% on an organic basis.[1]

(Logo:  http://photos.prnewswire.com/prnh/20120206/NE47232LOGO )

Brian Concannon, Haemonetics' President and CEO, commented: "The highlights of our second quarter were the successful acquisition of the whole blood business and continued organic revenue growth in disposables across our entire product portfolio, especially in our Hospital business where 14% second quarter growth followed 11% growth in the first quarter.  Strong demand for the Cell Saver® Elite® and TEG® disposables, and growth in our OrthoPAT® business, provide strong evidence that our Hospital customers continue to embrace our Blood Management Solutions recognizing the inherent value proposition offered."   

STRATEGIC AND PRODUCT GROWTH HIGHLIGHTS

Haemonetics continues to make progress expanding its business, reporting the following highlights:

  • 22% revenue growth including 6% organic revenue growth.
  • 7% revenue growth in plasma disposables.
  • 16% revenue growth in surgical disposables.
  • 23% revenue growth in diagnostic disposables.
  • 5% revenue growth in OrthoPAT disposables, a return to growth as expected.
  • 21% organic revenue growth in China.
  • $29 million of revenue from whole blood with uninterrupted customer service.
  • Announced two-for-one stock split.

A revenue breakdown follows:

Plasma

Plasma disposables revenue was $68.7 million, up 7% and growth in North America was up 10%.  On a year-to-date basis, global plasma revenue is up 4%.  The Company continues to expect its plasma business to grow 4-6% in fiscal 2013 consistent with end market growth rates for plasma derived biopharmaceuticals.

Blood Center

Platelet disposables revenue was $43.2 million, up 2% over the prior year's second fiscal quarter, with continued benefit from strong sales in emerging markets.  Red cell disposables revenue was $11.9 million, up 2%.  Though the clinical demand for blood remained flat, red cell revenue grew on increased collections as the Company leveraged its IMPACT® selling approach to advance Blood Management Solutions.

On a year-to-date basis, blood center revenue is up 1% organically and the Company continues to expect its blood center business to grow 0-2% organically in fiscal 2013, with continued growth in both platelet and red cell disposables as the year progresses.  Whole blood revenue of $29 million was in line with expectations considering buy-ins by customers in advance of the ownership transfer.  The Company is affirming its previous guidance for whole blood revenue of $135-$145 million.     

Hospital

Surgical disposables revenue was $18.8 million in the quarter, up 16%.  Notably this was the fifth consecutive quarterly increase, as the product launch of the Cell Saver Elite device continues to accelerate.  Recent strong Cell Saver Elite equipment sales drove near term disposables growth. 

Disposables revenue from the OrthoPAT orthopedic perioperative autotransfusion system was $7.6 million in the quarter, up 5% following a prior quarter decline of 3% and a full fiscal 2012 decline of 12%.  The impact of the fiscal 2012 voluntary recall of pre-2002 devices upon disposables usage has ended and the expected return to growth has begun.  

Diagnostics revenue was $6.9 million in the quarter, up 23%, as the Company's IMPACT initiative continues to drive growth in disposables utilized in the TEG® Thrombelastograph® Hemostasis Analyzer.  TEG equipment sales were especially strong in recent quarters, a key indicator for near term future disposables revenue growth. TEG disposables sales also increased 23% in China.  

On a year-to-date basis, Hospital revenue is up 13% and the Company continues to expect its hospital business to grow 12-15% in fiscal 2013 with continued strength in surgical and diagnostics disposables, and continued OrthoPAT disposables revenue growth.

Software and Equipment

Software Solutions revenue was $18.0 million, up 5%.  The enhanced offering of software products for Blood Center and Hospital customers drove revenue growth of 10% in North America.  On a year-to-date basis, software revenue is flat with prior year levels and trending upward, thus the Company continues to expect its software business to grow 5-7% in fiscal 2013.  

Equipment and other revenue was $14.3 million, down 3% following several quarters with strong double-digit percentage growth.  Equipment revenue is influenced by the timing of tenders and capital budgets and on a year-to-date basis, Equipment revenue is up 7%.  Sales of Cell Saver Elite and TEG devices in emerging markets continue to be particularly strong.

Haemonetics reported second quarter fiscal 2013 organic revenue growth of 8% in North America and 10% in Asia, along with a 2% decline in Europe.  Organic revenue growth in Japan was 6%.

Adjusted gross profit was $111.6 million up $20.2 million or 22.1%.  Adjusted gross margin was 51.0%, up 10 basis points, as benefits in the core business were more than sufficient to offset the impact of revenue mix toward lower margin whole blood disposables.

Adjusted operating expenses were $78.0 million, up $12.2 million or 18.5%.  Operating expense increases included $8.0 million in the new whole blood business and planned investments in global growth initiatives, emerging markets and infrastructure to support anticipated organic and acquisitive revenue growth; these expenses are expected to accelerate in the second half of the fiscal year.  Additionally, a full accrual of performance based compensation was provided in the second quarter of fiscal 2013.

Adjusted operating margin of 15.4% was up 120 basis points and reflected the inclusion of only seven weeks' profits of the newly acquired whole blood business.  Operating margin benefited from a managed ramp-up of investments in global growth initiatives and certain expenditures related to infrastructure build for the acquired whole blood business. 

Acquisition related amortization expense included in second quarter adjusted earnings was $5.7 million in fiscal 2013 and $2.5 million in fiscal 2012, or $0.14 and $0.06 per share respectively.  Year-to-date adjusted earnings included $8.3 million in fiscal 2013 and $5.0 million in fiscal 2012, or $0.22 and $0.12 per share respectively, of acquisition-related amortization expense.

Balance Sheet and Cash Flow

Cash on hand was $187 million, a decrease of $49 million during the quarter, as the Company utilized $60 million of cash toward the whole blood business acquisition.  The Company reported first half free cash flow before restructuring, transformation, integration and transaction costs of $22 million, a reduced level from the prior year due to an anticipated buildup of certain required elements of working capital not acquired.

Fiscal 2013 Guidance and Fiscal 2014 Outlook

The Company reaffirmed its previous fiscal 2013 organic revenue growth expectation of approximately 4-6%, with plasma expected to grow 4-6%, Blood Center 0-2%, Hospital products 12-15%, and Software Solutions 5-7%.  Whole blood revenue expectations are also reaffirmed at approximately $135-$145 million for fiscal 2013. Thus, total revenue is estimated in the range of $890-$915 million, up 23-26%.

Full year adjusted gross margin is expected to be in a range of 50-51% inclusive of the lower gross margin whole blood product line.  Adjusted operating income is expected to be between $127-$130 million, and free cash flow will approximate $85 million before funding restructuring, transformation and transaction costs.  The paced ramp-up of expenses is expected to accelerate in the second half of the year.  Accordingly, the previously indicated adjusted earnings per share range of $3.30-$3.40, up 9%-12% over fiscal 2012, is also reaffirmed.  Whole blood profits, IT and other costs of scaling the Company's infrastructure to meet the needs of the combined businesses, as well as amortization expenses, financing costs and income taxes are included in adjusted earnings projections.

The Company continues to expect to incur costs in the current fiscal year for integration activities of $30-$35 million, which are excluded from adjusted earnings guidance.  Annual guidance also assumes the exclusion of approximately $3 million of transaction related costs and approximately $13 million of adjustments to cost of goods sold on the sale of acquired whole blood and other filter inventories.  The Company also expects to incur restructuring and transformation costs within the base business of $3-$4 million which are excluded from adjusted earnings guidance.  

More information on fiscal year 2013 guidance, including income statement scenarios underlying the lower and upper ends of the adjusted earnings per share guidance range, can be found in the Investor Relations section of our web site at http://www.haemonetics.com.[1]

For fiscal 2014, previous indications are affirmed, as organic revenue growth is expected to approximate 5-7%.  Together with a full year of revenues from the acquired whole blood business, which is expected to contribute incremental revenue of $70 million related to the timing of the acquisition, fiscal 2014 revenues are expected to surpass $1 billion.  The Company's previously provided preliminary outlook for fiscal 2014 adjusted earnings per share of $3.90-$4.10, approximately 20% above fiscal 2013 expected earnings per share, is affirmed.  Included in these amounts are approximately $29 million or $0.75 per share of acquisition related amortization expense.

Mr. Concannon added: "While completing the largest acquisition in our company's history, our team remained customer focused and delivered excellent second quarter results.  This included solid organic revenue growth of 6%, $29 million of whole blood revenue realized through seamless customer ordering, and effective cost management.  We remain confident in our business fundamentals and are able to reaffirm the fiscal 2013 revenue and earnings guidance, and the fiscal 2014 preliminary outlook that we previously provided."

Stock Split

The Company announced today that its Board of Directors approved a two-for-one split of the Company's common stock, which will be effected in the form of a 100 percent stock dividend.  The stock dividend will be distributed November 30 to stockholders of record as of November 9.  Haemonetics' common stock will begin trading on a post-split basis on the New York Stock Exchange on December 3, 2012. 

Each share of the Company's pre-split common stock held by a shareholder, including shares subject to outstanding stock options and shares available for grant under the Company's equity incentive plans, will be represented by two shares of the Company's post-split common stock.  The split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage.

The Company expects that this split will make its shares more accessible, increase its shareholder base and improve its market liquidity.  With the Company's recent growth, long term shareholder value creation and its most significant acquisition recently completed, the stock split also reflects confidence in the Company's strength and ability to continue to generate long term growth and financial performance.

Fiscal 2013 Share Repurchase Program

The Company repurchased 74,300 shares in the open market at an average cost of $71.91, returning $5.3 million to shareholders during the second quarter.  The Board of Directors previously approved the repurchase of up to $50 million of shares in the open market during the remainder of fiscal 2013.

CONFERENCE CALL

Haemonetics will host a webcast to discuss the first quarter results on Monday, October 29, 2012 at 8:00 am Eastern time.  Interested parties can participate at: http://phoenix.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4839735.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world.  Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.  To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

This release contains forward-looking statements that involve risks and uncertainties, including the effects of disruption from the acquisition of the Pall Transfusion Medicine business making it more difficult to maintain relationships with employees, customers, vendors and other business partners, unexpected expenses incurred to integrate the Pall Transfusion Medicine business, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, product quality, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. 

Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict.  Actual results and experience could differ materially from the forward-looking statements. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.

[1] A reconciliation of GAAP to adjusted financial results is included at the end of the financial sections of this press release as well as on the web at http://www.haemonetics.com.  GAAP results include the following items which are excluded from adjusted results: $14 million of pre-tax integration, transaction and base business restructuring and transformation costs in the second quarter of fiscal 2013 and $9 million of pre-tax restructuring and transformation costs and $2 million of contingent consideration income in the second quarter of fiscal 2012.  The $14 million pre-tax amount in the second quarter of fiscal 2013 includes: $11 million of integration costs, $1 million of transaction costs and $2 million of base business restructuring and transformation costs.  Additionally, cost of goods sold in the second quarter of fiscal 2013 GAAP results include $10 million attributable to amounts in excess of manufactured cost of acquired whole blood and other filter inventory sold during the quarter.  Because such amounts are limited to the whole blood and other filter inventory on hand at the date of the acquisition and do not reflect the ongoing profitability of the acquired business, they have also been excluded from adjusted results.     

 

Haemonetics Corporation Financial Summary

(Unaudited data in thousands, except per share data)

Consolidated Statements of Income for the Second Quarter of FY13 and FY12












9/29/2012


10/1/2011


% Inc/(Dec)




As Reported


As Reported


vs Prior Year

Net revenues


$

218,178



$

179,445



21.6

%

Gross profit


101,762



89,949



13.1

%










R&D


10,827



10,350



4.6

%


S,G&A


81,034



62,613



29.4

%


Contingent consideration income




(1,580)




Operating expenses


91,861



71,383



28.7

%









Operating income


9,901



18,566



(46.7)

%









Other income (expense), net


(1,311)



445



-










Income before taxes


8,590



19,011



(54.8)

%









Tax expense


2,043



5,131



(60.2)

%









Net income


$

6,547



$

13,880



(52.8)

%
















Net income per common share assuming dilution


$

0.25



$

0.54



(53.7)

%









Weighted average number of shares:








Basic


25,710



25,418





Diluted


26,157



25,843




















Profit Margins:






Inc/(Dec) vs prior year profit margin %

Gross profit


46.6

%


50.1

%


(3.5)

%

R&D


5.0

%


5.8

%


(0.8)

%

S,G&A


37.1

%


34.9

%


2.2

%

Operating income


4.5

%


10.3

%


(5.8)

%

Income before taxes


3.9

%


10.6

%


(6.7)

%

Net income


3.0

%


7.7

%


(4.7)

%















 

Haemonetics Corporation Financial Summary

(Unaudited data in thousands, except per share data)

Consolidated Statements of Income for Year-to-Date FY13 and FY12












9/29/2012


10/1/2011


% Inc/(Dec)




As Reported


As Reported


vs Prior Year

Net revenues


$

394,653



$

350,014



12.8

%

Gross profit


191,875



178,698



7.4

%










R&D


20,235



18,959



6.7

%


S,G&A


148,659



118,844



25.1

%


Contingent consideration income




(1,580)



(100.0)

%

Operating expenses


168,894



136,223



24.0

%









Operating income


22,981



42,475



(45.9)

%









Other income (expense), net


(975)



230



-










Income before taxes


22,006



42,705



(48.5)

%









Tax expense


5,671



11,877



(52.3)

%









Net income


$

16,335



$

30,828



(47.0)

%
















Net income per common share assuming dilution


$

0.63



$

1.18



(46.6)

%









Weighted average number of shares:








Basic


25,596



25,575





Diluted


26,044



26,029




















Profit Margins:






Inc/(Dec) vs prior year profit margin %

Gross profit


48.6

%


51.1

%


(2.5)

%

R&D


5.1

%


5.4

%


(0.3)

%

S,G&A


37.7

%


34.0

%


3.7

%

Operating income


5.8

%


12.1

%


(6.3)

%

Income before taxes


5.6

%


12.2

%


(6.6)

%

Net income


4.1

%


8.8

%


(4.7)

%

 














Revenue Analysis for the Second Quarter and Year-To-Date FY13 and FY12

(Unaudited data in thousands)






Three Months Ended



9/29/2012


10/1/2011


% Inc/(Dec)



As Reported


As Reported


vs Prior Year

Revenues by geography







United States

$

113,015



$

86,339



30.9

%


International

105,163



93,106



12.9

%

Net revenues

$

218,178



$

179,445



21.6

%








Disposable revenues














Plasma disposables

$

68,677



$

64,408



6.6

%









Blood center disposables







Platelet

43,198



42,195



2.4

%


Red cell

11,918



11,645



2.3

%


Whole blood

28,620








83,736



53,840



55.5

%


Hospital disposables







Surgical

18,804



16,206



16.0

%


OrthoPAT

7,645



7,295



4.8

%


Diagnostics

6,937



5,659



22.6

%



33,386



29,160



14.5

%









Subtotal

185,799



147,408



26.0

%








Software solutions

18,043



17,199



4.9

%

Equipment & other

14,336



14,838



(3.4)

%

Net revenues

$

218,178



$

179,445



21.6

%

















Six Months Ended



9/29/2012


10/1/2011


% Inc/(Dec)



As Reported


As Reported


vs Prior Year

Revenues by geography







United States

$

200,922



$

172,734



16.3

%


International

193,731



177,280



9.3

%

Net revenues

$

394,653



$

350,014



12.8

%








Disposable revenues














Plasma disposables

$

132,555



$

127,168



4.2

%









Blood center disposables







Platelet

80,440



79,504



1.2

%


Red cell

23,986



23,514



2.0

%


Whole blood

28,620








133,046



103,018



29.1

%


Hospital disposables







Surgical

37,064



31,948



16.0

%


OrthoPAT

15,186



15,049



0.9

%


Diagnostics

13,436



11,273



19.2

%



65,686



58,270



12.7

%









Subtotal

331,287



288,456



14.8

%








Software solutions

35,347



35,359



%

Equipment & other

28,019



26,199



6.9

%

Net revenues

$

394,653



$

350,014



12.8

%


 












Consolidated Balance Sheets

(Unaudited data in thousands)








As of




9/29/2012


3/31/2012







Assets




Cash and cash equivalents

$

187,051



$

228,861


Accounts receivable, net

158,175



135,464


Inventories, net

173,506



117,163


Other current assets

58,068



45,641




Total current assets

576,800



527,129


Net PP&E

239,160



161,657


Other assets

638,595



222,349









   Total assets

$

1,454,555



$

911,135























As of




9/29/2012


3/31/2012







Liabilities & Stockholders' Equity




Short term debt & current maturities

$

4,249



$

894


Other current liabilities

151,945



129,850




Total current liabilities

156,194



130,744


Long-term debt

477,402



2,877


Other long-term liabilities

48,993



44,883


Stockholders' equity

771,966



732,631









Total liabilities & stockholders' equity

$

1,454,555



$

911,135



 










Free Cash Flow Reconciliation

(Unaudited data in thousands)




Three Months Ended


9/29/2012


10/1/2011





GAAP cash flow from operations

$

33,014



$

25,408






Capital expenditure

(25,991)



(12,042)


Proceeds from sale of property, plant and equipment

103



111


Net investment in property, plant and equipment

(25,888)



(11,931)






Free cash flow after restructuring and transformation costs

7,126



13,477






Restructuring and transformation costs

11,541



2,807






Free cash flow before restructuring and transformation costs

$

18,667



$

16,284















Six Months Ended


9/29/2012


10/1/2011





GAAP cash flow from operations

$

33,567



$

52,539






Capital expenditure

(34,432)



(23,843)


Proceeds from sale of property, plant and equipment

355



130


Net investment in property, plant and equipment

(34,077)



(23,713)






Free cash flow after restructuring and transformation costs

(510)



28,826






Restructuring and transformation costs

22,286



4,585






Free cash flow before restructuring and transformation costs

$

21,776



$

33,411


 







Haemonetics Corporation Financial Summary

Reconciliation of Non-GAAP Measures











Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.






These measures are used by management to monitor the financial performance of the business, inform business decision making, and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring and transformation costs and certain cost of goods sold related to the acquisition of Pall's Transfusion Medicine Business ("Whole Blood Acquisition") from our GAAP expenses.  Our restructuring and transformation costs in fiscal 2013 are principally related to transaction and integration expenses related to the Whole Blood Acquisition.  The cost of goods sold removed from GAAP expenses related to the Whole Blood Acquisition principally relate to the increase in the fair value of acquired whole blood inventory required under purchase accounting standards.    We believe this information is useful for investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.






Non-GAAP Gross Profit

The use of these non-GAAP measures allows management to monitor the level of total gross profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.






Non-GAAP S,G&A and Non-GAAP Operating Expenses

The use of this non-GAAP measure allows management to monitor the ongoing level of spend that is necessary to support the business in a period when we are not transforming our business or completing an acquisition of in-process research and development. We establish our budgets, forecasts, and performance targets excluding these costs.






Non-GAAP Operating Income and Non-GAAP Income before Income Taxes

The use of these non-GAAP measures allows management to monitor the level of operating and total pre-tax profits without the costs of our business transformation. We establish our budgets, forecasts, and performance targets on this basis.






Non-GAAP Net Income and Earnings per Share

The use of these non-GAAP measures allows management to monitor the level of net income and earnings per share excluding both the costs of our business transformation, as well as any related tax effects. We establish our budgets, forecasts, and performance targets on this basis.

















Reconciliation of Non-GAAP Measures for the Second Quarter of FY13 and FY12








Three Months Ended



9/29/2012


10/1/2011






Non-GAAP gross profit





GAAP gross profit


$

101,762



$

89,949


Whole Blood Acquisition cost of goods sold adjustment



9,788






Restructuring and transformation costs





1,381


Non-GAAP gross profit


$

111,550



$

91,330







Non-GAAP R&D





GAAP R&D


$

10,827



$

10,350


Restructuring and transformation costs


(1,592)



(1,356)


Non-GAAP R&D


$

9,235



$

8,994







Non-GAAP S,G&A





GAAP S,G&A


$

81,034



$

62,613


Restructuring and transformation costs


(12,287)



(5,792)


Non-GAAP S,G&A


$

68,747



$

56,821







Non-GAAP operating expenses





GAAP operating expenses


$

91,861



$

71,383


Restructuring and transformation costs


(13,879)



(7,148)


Contingent consideration income




1,580


Non-GAAP operating expenses


$

77,982



$

65,815







Non-GAAP operating income





GAAP operating income


$

9,901



$

18,566


Restructuring and transformation costs


23,667



8,529


Contingent consideration income




(1,580)


Non-GAAP operating income


33,568



$

25,515







Non-GAAP income before taxes





GAAP income before taxes


$

8,590



$

19,011


Restructuring and transformation costs


23,667



8,529


Contingent consideration income




(1,580)


Non-GAAP income before taxes


$

32,257



$

25,960







Non-GAAP net income





GAAP net income


$

6,547



$

13,880


Restructuring and transformation costs


23,667



8,529


Contingent consideration income




(1,580)


Tax benefit associated with non-GAAP items


(6,684)



(2,164)


Non-GAAP net income


$

23,530



$

18,665







Non-GAAP net income per common share assuming dilution





GAAP net income per common share assuming dilution


$

0.25



$

0.54


Non-GAAP items after tax per common share assuming dilution


$

0.65



0.18


Non-GAAP net income per common share assuming dilution


$

0.90



$

0.72












Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.








Three Months Ended



9/29/2012


10/1/2011

Non-GAAP revenues





GAAP revenue


$

218,178



$

179,445


Foreign currency effects


(14,983)



(13,544)


Non-GAAP revenue - constant currency


$

203,195



$

165,901







Non-GAAP net income





Non-GAAP net income, adjusted for restructuring and transformation costs


$

23,530



$

18,665


Foreign currency effects


(6,880)



(3,213)


Income tax associated with foreign currency effects


1,861



903


Non-GAAP net income - constant currency


$

18,511



$

16,355







Non-GAAP net income per common share assuming dilution





Non-GAAP net income per common share assuming dilution, adjusted for restructuring and transformation costs


$

0.90



$

0.72


Foreign currency effects after tax per common share assuming dilution


$

(0.19)



$

(0.09)


Non-GAAP net income per common share assuming dilution - constant currency


$

0.71



$

0.63



Reconciliation of Non-GAAP Measures for FY13 and FY12








Six Months Ended



9/29/2012


10/1/2011

Non-GAAP gross profit





GAAP gross profit


$

191,875



$

178,698









Whole Blood Acquisition cost of goods sold adjustment


9,788





Restructuring and transformation costs





1,381


Non-GAAP gross profit


$

201,663



$

180,079







Non-GAAP R&D





GAAP R&D


$

20,235



$

18,959


Restructuring and transformation costs


(2,134)



(1,356)


Non-GAAP R&D


$

18,101



$

17,603







Non-GAAP S,G&A





GAAP S,G&A


$

148,659



$

118,844


Restructuring and transformation costs


(18,183)



(6,129)


Non-GAAP S,G&A


$

130,476



$

112,715







Non-GAAP operating expenses





GAAP operating expenses


$

168,894



$

136,223


Restructuring and transformation costs


(20,317)



(7,485)


Contingent consideration income




1,580


Non-GAAP operating expenses


$

148,577



$

130,318







Non-GAAP operating income





GAAP operating income


$

22,981



$

42,475


Restructuring and transformation costs


30,105



8,865


Contingent consideration income




(1,580)


Non-GAAP operating income


$

53,086



$

49,760







Non-GAAP income before taxes





GAAP income before taxes


$

22,006



$

42,705


Restructuring and transformation costs


30,105



8,865


Contingent consideration income




(1,580)


Non-GAAP income before taxes


$

52,111



$

49,990







Non-GAAP net income





GAAP net income


$

16,335



$

30,828


Restructuring and transformation costs


30,105



8,865


Contingent consideration income




(1,580)


Tax benefit associated with non-GAAP items


(8,565)



(2,350)


Non-GAAP net income


$

37,875



$

35,763







Non-GAAP net income per common share assuming dilution





GAAP net income per common share assuming dilution


$

0.63



$

1.18


Non-GAAP items after tax per common share assuming dilution


$

0.82



$

0.19


Non-GAAP net income per common share assuming dilution


$

1.45



$

1.37













Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.








Six Months Ended



9/29/2012


10/1/2011

Non-GAAP revenues





GAAP revenue


$

394,653



$

350,014


Foreign currency effects


(27,800)



(24,607)


Non-GAAP revenue - constant currency


$

366,853



$

325,407







Non-GAAP net income





Non-GAAP net income, adjusted for restructuring, transformation costs and contingent consideration income


$

37,875



$

35,763


Foreign currency effects


(11,519)



(6,416)


Income tax associated with foreign currency effects


3,148



1,827


Non-GAAP net income - constant currency


$

29,504



$

31,174







Non-GAAP net income per common share assuming dilution





Non-GAAP net income per common share assuming dilution, adjusted for restructuring, transformation costs and contingent consideration income


$

1.45



$

1.37


Foreign currency effects after tax per common share assuming dilution


$

(0.32)



$

(0.18)


Non-GAAP net income per common share assuming dilution - constant currency


$

1.13



$

1.19


 

 

Restructuring, Transformation and Other costs

 

(in thousands)

 

GAAP results include the following items which are excluded from adjusted results








Three Months Ended



9/29/2012


10/1/2011

Whole Blood acquisition cost of goods sold adjustments


$

9,788



$

-


Integration


10,811



-


HS Core



4




3,217


Restructuring and transformation



2,361




5,322











Transaction costs


703





Total restructuring, transformation and other costs


$

23,667



$

8,529














Six Months Ended



9/29/2012


10/1/2011

Whole Blood acquisition cost of goods sold adjustments


$

9,788



$

-


Integration


14,606



-


HS Core



(977)




3,217


Restructuring and transformation



3,901




5,648











Transaction costs


2,787





Total restructuring, transformation and other costs


$

30,105



$

8,865


 

CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
gerry.gould@haemonetics.com
Alt. (781) 356-9613

SOURCE Haemonetics Corporation



RELATED LINKS
http://www.haemonetics.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.